Author:
Maeda Kazuya,Sugiyama Yuichi
Subject
Clinical Biochemistry,Molecular Biology,Molecular Medicine,General Medicine,Biochemistry
Reference39 articles.
1. Agarwal, S., Arya, V., Zhang, L., in press. Review of P-gp inhibition data in recently approved new drug applications: utility of the proposed [I1]/IC50 and [I2]/IC50 criteria in the P-gp decision tree. J. Clin. Pharmacol.
2. Gemfibrozil greatly increases plasma concentrations of cerivastatin;Backman;Clin. Pharmacol. Ther.,2002
3. P-glycoprotein: tissue distribution, substrates, and functional consequences of genetic variations;Cascorbi;Handb. Exp. Pharmacol.,2011
4. Refining the in vitro and in vivo critical parameters for P-glycoprotein, [I]/IC50 and [I2]/IC50, that allow for the exclusion of drug candidates from clinical digoxin interaction studies;Cook;Mol. Pharm.,2010
5. European Medicines Agency (EMA), 2012, Guideline on the Investigation of Drug Interactions. .
Cited by
39 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献